Trial Profile
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Esmethadone (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Relmada Therapeutics
- 04 Apr 2022 According to a Relmada Therapeutics media release, data from the study will be presented at the Ketamine & Related Compounds International Hybrid Conference 2022.
- 22 Dec 2021 Results published in the American Journal of Psychiatry
- 22 Dec 2021 According to a Relmada Therapeutics media release, results from this trial were published in the peer-reviewed American Journal of Psychiatry.